Any contraindications that apply to peg-IFN and RBV apply to<unk>  since they must be used in combination during treatment of CHC. For example, people with sickle cell anemia are contraindicated to RBV therapy and are therefore contraindicated to<unk>  and peg-IFN combination therapy. Pregnant women and men whose female partners are pregnant are contraindicated for<unk>  since peg-IFN and RBV are known to cause birth defects. Pregnancy<unk>  is avoided in pregnant women or women planning to be pregnant because it going to be taken with RBV and Peg-IFN, which have both shown to cause fetal problems in animal studies. RBV has been shown to cause birth defects and fetal deaths in animal studies. Peg-IFN has been shown to cause abortions in animal studies. People must have a negative pregnancy test prior to starting therapy, use at least two effective birth control methods during treatment, and undergo monthly pregnancy tests. If pregnant women are exposed to any medication regimen containing ribavirin, they are encouraged to report this through the ribavirin pregnancy registry.
Simeprevir
Saquinavir
Telaprevir
Fosamprenavir
Glecaprevir
Abacavir
Indinavir
Fostemsavir